Other

Cognetix, Inc.

David Griffen

Baldomero M Olivera

David R Hillyard

Lourdes J Cruz

Maren Watkins

Julita S Imperial

A Grey Craig

Robert M Jones

R Tyler McCabe

Richard T Layer

John D Wagstaff

The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr -contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinson's disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourette's syndrome, Huntington's chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.

Contulakin-G, analogs thereof and uses therefor

Contulakin-G, analogs thereof and uses thereof

Growing community of inventors

Greenville, NC, United States of America

David Griffen